Bioversys AG has divulged compounds with the ability to interact with accessory gene regulator A (AgrA) and inhibit the expression of AgrA-regulated virulence factors.
Researchers from Scynexis Inc. have recently presented details on the preclinical characterization of SCY-247, a second-generation triterpenoid with glucan synthase inhibitor activity and intended to be used for the treatment of invasive mucormycosis.
When a cell is invaded by a virus, the cell triggers an innate immune response by activating retinoic acid-inducible gene I (RIG-I) like receptors (RLRs), among others, that are essential for controlling viral replication. Even though several ubiquitin ligases (E3) have been identified to positively or negatively regulate RLRs post-translationally, the E3 ligases directly involved in RLR transcription are still unknown. A screening including 375 ubiquitin E3 ligases identified E3 ubiquitin-protein ligase UBR5 as a positive regulator of RLR transcription.
Be it viral, nucleic acid or protein vaccines, recent efforts that led to the first regulatory approvals for not only COVID-19, but also for malaria and respiratory syncytial virus, positioned infectious diseases in the headlines for much of the last four years. But despite that attention, or the threat of future pandemics, or the numerous infectious diseases for which there are no preventable vaccines and very little development activity, the level of private and public funding for biopharma companies working in the space is dismal – at least compared with that of oncology products, according to a new analysis report released by the Biotechnology Innovation Organization (BIO) on Jan. 25.
Naegleria fowleri, colloquially known as the "brain-eating amoeba," is a water-borne amoeba and the leading cause of primary amoebic meningoencephalitis (PAM). In a recent study published in Scientific Reports, researchers from the University of Central Punjab aimed to design an mRNA-based vaccine against PAM.
To combat trypanosomiasis and leishmaniasis, researchers from the University of Modena and Reggio Emilia and collaborators conducted a study focusing on pteridine reductase 1 (PTR1), a catalytic protein crucial to the folate metabolic pathway in Trypanosomatid parasites.
Researchers at ETH Zurich have identified a proteomic signature that could recognize long COVID six months after acute infection. Biologically, the signature indicated that the complement system remained active in patients with long COVID six months after infection. Translationally, it could lead to a diagnostic test for long COVID, and suggests that targeting the complement system could be a therapeutic approach to prevent or treat the disorder.
Bioversys AG has described 3-(phenylsulfonyl)-[1,2,3]triazolo[1,5a]quinazolin-5(4h)-one derivatives with the ability to interact with accessory gene regulator A (AgrA) and inhibit the expression of AgrA-regulated virulence factors reported to be useful for the treatment of bacterial infections and skin inflammation.
RSS
